The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow
- PMID: 19638319
- DOI: 10.1016/j.drudis.2009.07.004
The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow
Abstract
Since the development of the first cytotoxic agents, synthetic organic chemistry has advanced enormously. The synthetic and medicinal chemists of today are at the centre of drug development and are involved in most, if not all, processes of drug discovery. Recent decreases in government funding and reformed educational policies could, however, seriously impact on drug discovery initiatives worldwide. Not only could these changes result in fewer scientific breakthroughs, but they could also negatively affect the training of our next generation of medicinal chemists.
Similar articles
-
Anticancer drug discovery in the future: an evolutionary perspective.Drug Discov Today. 2009 Dec;14(23-24):1136-42. doi: 10.1016/j.drudis.2009.09.006. Epub 2009 Oct 1. Drug Discov Today. 2009. PMID: 19800414 Review.
-
Chemistry strategies in early drug discovery: an overview of recent trends.Drug Discov Today. 2008 Aug;13(15-16):677-84. doi: 10.1016/j.drudis.2008.03.007. Epub 2008 May 2. Drug Discov Today. 2008. PMID: 18675762 Review.
-
Chemical approaches to the discovery and development of cancer therapies.Nat Rev Cancer. 2005 Apr;5(4):285-96. doi: 10.1038/nrc1587. Nat Rev Cancer. 2005. PMID: 15803155 Review.
-
Drug discovery chemistry: a primer for the non-specialist.Drug Discov Today. 2009 Aug;14(15-16):731-44. doi: 10.1016/j.drudis.2009.04.005. Epub 2009 May 4. Drug Discov Today. 2009. PMID: 19416759 Review.
-
Is chemical synthetic accessibility computationally predictable for drug and lead-like molecules? A comparative assessment between medicinal and computational chemists.Eur J Med Chem. 2012 Aug;54:679-89. doi: 10.1016/j.ejmech.2012.06.024. Epub 2012 Jun 21. Eur J Med Chem. 2012. PMID: 22749644
Cited by
-
Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold.Pharmaceuticals (Basel). 2022 Nov 15;15(11):1416. doi: 10.3390/ph15111416. Pharmaceuticals (Basel). 2022. PMID: 36422546 Free PMC article.
-
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity.Medchemcomm. 2019 Jun 27;10(8):1476-1480. doi: 10.1039/c9md00201d. eCollection 2019 Aug 1. Medchemcomm. 2019. PMID: 31673310 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources